A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.106_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

British Journal of Haematology
Hematology
2016English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

American Journal of Hematology
Hematology
2018English

Safety and Clinical Activity of Temsirolimus in Combination With Rituximab and Dhap in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma-Report of the Prospective, Multicenter Phase Ii Storm Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase Ii Study of Durvalumab (Anti-Pd-L1) Combined With Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Accept: A Phase Ib/Ii Combination of Acalabrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-Chop) for Patients With Diffuse Large B-Cell Lymphoma (Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy